Table 1 Demographic and clinical data at the onset of the disease
From: The impact of IgM deposits on the outcome of Nephrotic syndrome in children
IgM + (n = 18) | IgM – (n = 27) | p value | |
|---|---|---|---|
First manifestation | |||
Age, yearsa | 4.51 (0.96–14.23) | 4.09 (1.02–17.05) | 0.926 |
Gender, n (%) | 0.371 | ||
Boys | 12/18 (66.7) | 14/27 (51.9) | |
Girls | 6/18 (33.3) | 13/27 (48.1) | |
Clinical data, n (%) | |||
Hematuria | 13/18 (72.2) | 17/27 (63.0) | 0.748 |
Hypertension | 7/18 (38.9) | 11/27 (40.8) | 1 |
Decreased GFR | 2/18 (11.1) | 5/27 (18.5) | 0.684 |
Extrarenal symptoms | 5/18 (27.8) | 2/27 (7.4) | 0.098 |
Primary response to steroids, n (%) | |||
Sensitive | 10/18 (55.6) | 15/27 (55.6) | 1 |
Dependent | 2/18 (11.1) | 7/27 (25.9) | 0.279 |
Resistant | 6/18 (33.3) | 5/27 (18.5) | 0.304 |
Treatment, nb(%) | |||
Only steroids | 3/18 (16.7) | 8/27 (29.6) | 0.482 |
Cumulative dose of steroids | 523.3 mg/kg | 429.6 mg/kg | 0.8 |
Cyclosporine | 15/18 (83.3) | 18/27 (66.7) | 0.308 |
Mycophenolate mofetil | 4/18 (22.2) | 4/27 (14.8) | 0.694 |
Cyclophosphamide | 6/18 (33.3) | 9/27 (33.3) | 1 |
Rituximab | 3/18 (16.7) | 1/27 (3.7) | 0.286 |
Levomisole | 3/18 (16.7) | 4/27 (14.8) | 1 |
Biopsy results, n (%) | 0.049 | ||
Minimal change disease | 8/18 (44.4) | 16/27 (59.3) | |
Mesangial hypercellularity | 1/18 (5.6) | 6/27 (22.2) | |
Focal segmental glomerulosclerosis | 9/18 (50.0) | 5/27 (18.5) | |